From: Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
 | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
 | HR (95%CI) | P value | HR (95%CI) | P value |
ETV5 expression (low- vs over-expression) | 2.108(1.190–3.736) | 0.011* | 1.427(0.485–4.192) | 0.518 |
Age (<55 vs ≥ 55) | 0.534(0.322–0.885) | 0.015* | 0.713(0.379–1.340) | 0.293 |
FIGO stage (I-IIvsIII-IV) | 9.626(3.722–24.899) | ≤0.001*** | 5.301(1.564–1.973) | 0.007** |
Recurrence (no vs yes) | 2.542(1.178–5.482) | 0.017* | 2.670(1.140–6.253) | 0.024* |
Chemotherapy response (sensitive vs partial) | 0.967(0.520–1.798) | 0.915 |  |  |
Ascites (no vs yes) | 1.192(0.562–2.527) | 0.647 |  |  |